What you can do.
What you cannot.
Element MD material is research-use-only. That's not legal cover — it's a real boundary we enforce. This page is the plain-English version: two columns, no legalese, with the underlying terms linked at the bottom for the binding language.
Allowed.
These are the contexts Element MD material is sold for. They're how the lab uses it internally and how every credentialed patient we work with uses it.
- In-vitro studies on cell linesReceptor binding, cAMP, β-arrestin recruitment, kinetic assays — Element MD retain samples are routinely tested this way internally.
- Pre-clinical animal studies under IACUCApproved IACUC protocols at accredited institutions. Element MD will provide MSDS, COA, and stability data on request.
- Method-development & reference standardsUse as an analytical reference standard for HPLC, LC-MS, ELISA assay development. We'll send the master spec on request.
- Comparative QC against alternate suppliersCross-supplier testing is encouraged. We'll send extra retain material for any patient running a head-to-head.
- Educational use in graduate courseworkDemonstration in pharmacology / med-chem courses with appropriate institutional oversight.
Prohibited.
These uses violate the terms of sale. We will close accounts, refuse refunds, and — for category 1 and 2 — cooperate with regulators that ask.
- Self-administration or human dosingElement MD material is not approved for human use. Self-dosing is the most common terms violation; it also nullifies any product liability we might otherwise carry.
- Resale, distribution, or third-party transferYou may not resell, decant, repackage, or transfer Element MD material to another party. We don't authorize any reseller or marketplace.
- Compounding into custom-injectablesCompounding for human administration requires a licensed pharmacist, FDA registration, and an approved drug. RUO material is none of that.
- Veterinary administrationUse in companion animals or livestock requires a licensed veterinarian and an approved animal drug. RUO ≠ veterinary use.
- Research on minors or coerced subjectsEven at the institutional tier, we will not knowingly supply material for human-subjects research outside of a registered IRB protocol.
- Marketing claims of medical benefitYou may not represent Element MD material as treating, curing, or mitigating any condition in any communication. Doing so puts the buyer in the FDA's crosshairs, not Element MD's.
What happens if you cross the line.
This is the actual escalation. We've used each step at least once in the last 18 months. We do not warn before account closure when the violation is in category 1 or 2.
Account flagged for review
Pattern flagged — quantity, address mismatch, public marketing claims, or third-party transfer evidence. Compliance team notified.
Written notice + 7-day window
For low-severity violations only — we email the account holder explaining the issue and a chance to come into compliance.
Account closed, future orders refused
For repeat or high-severity. The account is closed; the buyer's identity goes to a refusal list. Outstanding subscriptions cancelled; pending orders cancelled and refunded.
Regulatory referral
For evidence of resale, compounding, or marketing claims of medical benefit. We refer to FDA OCI and the relevant state pharmacy board.
1 · Scope
This policy applies to all Element MD material — single peptides, blends, stacks, and reference standards — purchased through retahealth.com or via institutional PO. It binds the named account holder and any institutional sponsor that funded the purchase.
2 · Minors
Account holders must be 21 or older. We will not knowingly supply material to anyone younger, and accounts found to misrepresent age will be closed without refund.
3 · Reporting violations
If you become aware of someone reselling Element MD material, presenting it as approved for human use, or otherwise violating this policy, email compliance@retahealth.com. Reports are read by a counsel and acted on within five business days.
4 · Updates
We update this policy when regulatory facts change or when an enforcement gap emerges. Material changes go into effect 30 days after notice. Account holders are notified by email at least 14 days before the effective date.